Dr. James Cavanaugh
Mr. John Dee
Mr. Peter Johnson
Dr. Fernand Kaufmann
Mr. James Levine
Mr. Joshua Ruch
Ms. Cheryl Wenzinger
Mr. Michael Zak
Dr. James Cavanaugh
has been a director of Verenium since 1992 and Verenium's Chairman since 1998. Since 1988, Dr. Cavanaugh has served as a general partner of HealthCare Ventures LLC, a venture capital management company. Dr. Cavanaugh was formerly president of SmithKline & French Laboratories U.S., the pharmaceutical division of SmithKline Beckman Corporation. Previously, he was president of SmithKline Beckman's clinical laboratory business and, before that, president of Allergan International, a pharmaceutical company. Prior to his industry experience, Dr. Cavanaugh served in numerous senior posts with the U.S. Government on the White House Staff as staff assistant to the President for Health Affairs and then deputy director of the Domestic Council. He also served as deputy assistant to the President for Domestic Affairs and deputy chief of the White House staff. Prior to that, he was a member of the faculty of College of Medicine and the Graduate College at the University of Iowa.
back to top
Mr. John Dee
has been a director of Verenium since May 2008. He is currently Chairman of the Board of Neurophage, Inc., a pioneering neuroscience company focused on neurodegenerative disorders. He also served as Chairman of the Board of Bioprocessors, Inc., a leading innovator focused on advancements in bioprocessing for the Life Sciences industry, prior to its merger with Seahorse, Inc. Previously, he served as President and Chief Executive Officer of Hypnion, Inc. from its founding in 2000 until its sale to Eli Lilly in 2007 for $315 million. Under Mr. Dee's leadership, Hypnion raised approximately $70 million in venture capital, built a world-class scientific team and technology platform, advanced 5 drugs into clinical trials, and positioned itself as the leader in sleep discorder research and development. Prior to Hypnion, Mr. Dee spent a significant portion of is professional career with McKinsey & Co., Inc., where he conducted performance-improvement and strategic growth initiatives for several major energy and pharmaceutical companies. After leaving McKinsey in 1997, he conducted turnarounds of biotechnology companies as an acting Chief Executive Officer, including a successful restructuring of Genta, Inc. In non-profit pursuits, Mr. Dee led a group of Bay Area economists and business leaders in a diagnostic and public policy review of the San Francisco Bay Area's economic performance. He also advised the Pacific Presidio Center, a non-profit environmental group, on the potential redesign of the Presidio army base into a world environmental center. Mr. Dee holds a B.A. / M.S. in Engineering from Stanford University and an M.B.A. from Harvard University.
back to top
Mr. Peter Johnson
has been a director of Verenium since 1999. Mr. Johnson was a founder of Agouron Pharmaceuticals, Inc. and served as its president and chief executive officer from its inception in 1984 until 2000. Mr. Johnson currently serves as a director of a nonprofit organization. Mr. Johnson received a B.A. and an M.A. from the University of California.
back to top
Dr. Fernand Kaufmann
has been a director of Verenium since 2004. Dr. Kaufmann retired from The Dow Chemical Company, a public chemical manufacturing company, in 2001. During his over 33-year career at Dow, Dr. Kaufmann served in a number of senior executive capacities, including Group Vice-President for New Businesses and as a member of Dow's management executive committee. Dr. Kaufmann currently serves as chief executive officer and chairman of the board of HPL SA, a Swiss technology start-up company in the field of novel lithium-ion battery technology. He also serves as an advisor to Emerald Technology Ventures, a Swiss venture capital fund focused on clean energy and other technology. Dr. Kaufmann received a Ph.D. in Polymer Chemistry from the University of Strasbourg, France.
back to top
Mr. James Levine
became President, Chief Executive Officer and a member of the Board of Directors of Verenium in April 2011. He joined Verenium in April 2009 as Executive Vice President and Chief Financial Officer. Prior to joining Verenium, Mr. Levine held various positions focused on the energy and healthcare industries with the global investment banking and securities firm, Goldman Sachs & Co., where he most recently served as a Managing Director in the Power and Utilities Group in New York. Before that he served as a Managing Director in the Goldman Sachs Energy Group in London and held positions in the Goldman Sachs Healthcare Group in London and New York focused on biotechnology companies. Prior to Goldman Sachs, Mr. Levine held positions with Lehman Brothers, Inc. in New York, and Industrial Economics, Inc. in Cambridge, Massachusetts. Mr. Levine received an M.B.A. degree with a concentration in Finance from the Wharton School of the University of Pennsylvania and a B.A. in Economics from Brandeis University in Waltham, Massachusetts.
back to top
Mr. Joshua Ruch
has served as a director of Verenium since 2007, and prior to Verenium's merger with Celunol, was a director of Celunol. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an investment and venture capital management company, which he co-founded in 1981. Prior to founding Rho, Mr. Ruch was employed in investment banking at Salomon Brothers. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology (Technion) and an MBA from the Harvard Business School. Mr. Ruch is also a director of Genvec, Inc. (Nasdaq: GNVC) and a number of private companies.
back to top
Ms. Cheryl Wenzinger
has been a director of Verenium since 2004 and serves as the chair of Verenium's audit committee and as the audit committee's financial expert. In her most recent position as audit partner at Deloitte & Touche from 1984 to 2000, Ms. Wenzinger served many private and public companies, with a focus on health care providers and insurers, manufacturing, and agribusiness. She currently serves on the Board of Directors for Banner Health, where she chairs the audit committee and serves on the compensation committee, and the Board of Trustees for Delta Dental Plan of Colorado, where she serves on the audit committee as the financial expert. Ms. Wenzinger received a B.S. in Accounting from the University of Northern Colorado and is a Certified Public Accountant.
back to top
Mr. Michael Zak
has been a director of Verenium since 2007, and prior to Verenium's merger with Celunol, was a director of Celunol. Since 1991 Mr. Zak has been with Charles River Ventures, a venture capital management company, where he invests in alternative energy and fuel technologies among other industries including voice and data communications equipment, networking software, applications software and services, optical communications equipment, network monitoring and analysis software, semiconductors and wireless communications equipment. From 1986 to 1991 he served as co-founder and Vice President of Concord Communications, a start-up network monitoring and analysis software company which subsequently became a successful investment of Charles River Ventures. From 1981 to 1986 Mr. Zak was employed by Motorola, Inc. and McKinsey & Company, Inc., and from 1975 to 1979 he served as a communications and signals intelligence officer in the United States Marine Corps. Mr. Zak holds a B.S. degree in engineering from Cornell University and an M.B.A. from the Harvard Business School.
back to top
